Evidence map›Paper›PMID 32708464›Full record

ArticleInternational journal of molecular sciences2020

Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control.

Peng Guan, Robert Schaub, Kim E Nichols, Rupali Das

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Peng GuanDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Robert SchaubRGS Consulting, 118 Jeremy Hill Road Pelham, Pelham, NH 03076, USA.
Kim E NicholsDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0002-5581-6555
Rupali DasDepartment of Physiology, Michigan State University, East Lansing, MI 48824, USA.
Children's Hospital of Philadelphia · USMichigan State University · USSt. Jude Children's Research Hospital · US

Funding

Roles of CD2 and 2B4 in invariant natural killer T (iNKT) cell functions.K22CA188149 · NCI · MICHIGAN STATE UNIVERSITY · PI DAS, RUPALI · 2015 to 2017
$542k
NCI NIH HHS K22 CA188149
6 · The paper itself

Abstract

Invariant natural killer T (iNKT) cells are innate-like T lymphocytes characterized by the expression of an invariant T cell receptor (iTCR) that recognizes glycolipid antigens presented by the MHC I-like CD1d molecule. Following antigenic stimulation, iNKT cells rapidly produce large amounts of cytokines that can trans-activate dendritic cells (DC) and promote the anti-tumor functions of cytotoxic lymphocytes, such as natural killer (NK) and CD8 T cells. Additionally, iNKT cells can mediate robust and direct cytotoxicity against CD1d

Indexed as

AnimalsAntibodies, MonoclonalAntigens, CD1dCell Line, TumorCytokinesCytotoxicity, ImmunologicDrug SynergismDrug Therapy, CombinationImmunomodulationInterferon-gammaInterleukin-12LymphomaMiceMice, Inbred C57BLNatural Killer T-CellsReceptors, Antigen, T-CellAntibodies, MonoclonalAntigens, CD1dCd1d1 protein, mouseCytokinesInterferon-gammaInterleukin-12Receptors, Antigen, T-Cellcancer immunotherapyIL-12invariant natural killer T cellsmonoclonal antibodiesNKT14m

Identifiers

PMID32708464
PMCPMC7404385
OpenAlexW3042402624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.